We are live on
!
Find out more
AbCellera Biologics
ABCL
ABCL
203 hedge funds and large institutions have $1.3B invested in AbCellera Biologics in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 79 increasing their positions, 58 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
145% more call options, than puts
Call options by funds: $19M | Put options by funds: $7.75M
71% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 21
36% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 58
11% more capital invested
Capital invested by funds: $1.17B → $1.3B (+$129M)
7% more funds holding
Funds holding: 190 → 203 (+13)
1.99% more ownership
Funds ownership: 42.73% → 44.73% (+2%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Holders
203
Holders Change
+13
Holders Change %
+6.84%
% of All Funds
3.26%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.1%
New
36
Increased
79
Reduced
58
Closed
21
Calls
$19M
Puts
$7.75M
Net Calls
+$11.3M
Net Calls Change
-$27.6M
Top Buyers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$73.2M |
| 2 |
BlackRock
New York
|
+$14.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11.2M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$8.24M |
| 5 |
CC
Casdin Capital
New York
|
+$7.16M |
